Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy

Thomas Van Looy(KU Leuven), Patrick Schöffski(KU Leuven), Haifu Li(Brigham and Women's Hospital), Ulla Vanleeuw(KU Leuven), Jasmien Wellens(Brigham and Women's Hospital), Agnieszka Woźniak(VIB-KU Leuven Center for Cancer Biology), Giuseppe Floris(KU Leuven), Raf Sciot(KU Leuven), Paul W. Manley(Auckland City Hospital), Jonathan A. Fletcher(Harvard University), Maria Dêbiec‐Rychter(Center for Human Genetics)
Clinical Cancer Research
October 14, 2014
10.1158/1078-0432.ccr-14-1823
Cited by 50

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2016|766
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716